Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101

NCT03183934 is registered in ClinicalTrials.gov with Anterogen Co., Ltd. as lead sponsor.

NCT NCT03183934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03183934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101
Lead sponsor
Anterogen Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
December 8, 2017
Completion date
April 30, 2023
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dystrophic epidermolysis bullosa